TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16196417

Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (4.5 g/d for the first 4 months of lactation)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Fish oil supplementation
Number of subjects: 122

Group type: COMPARATOR
Intervention: Olive oil supplementation
Number of subjects: 122
Study: 12269727

Group type: EXPERIMENTAL
Intervention: Imagery training
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Traditional perceptual-motor training
Number of subjects: 54

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 54
Study: 9542208

Group type: EXPERIMENTAL
Intervention: Colony-stimulating factors (G-CSF and GM-CSF) as adjunctive care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no colony-stimulating factors)
Number of subjects: 0
Study: 7651658

Group type: EXPERIMENTAL
Intervention: nalbuphine 10 mg intravenously
Number of subjects: 28

Group type: COMPARATOR
Intervention: meperidine 50 mg intravenously
Number of subjects: 28
Study: 2682775

Group type: EXPERIMENTAL
Intervention: Intervention 1: Provision of information about the imager and nature of the examination
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Intervention 2: Information and counseling
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Intervention 3: Information and a 12-minute relaxation exercise
Number of subjects: 50
Study: 326593

Group type: EXPERIMENTAL
Intervention: Timolol maleate and bendrofluazide (10 mg timolol and 2-5 mg bendrofluazide, increased as needed)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 29497287

Group type: EXPERIMENTAL
Intervention: NEM 500 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 27143321

Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 4250

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4250
Study: 24884770

Group type: EXPERIMENTAL
Intervention: Mesh repair
Number of subjects: 346

Group type: COMPARATOR
Intervention: Patch repair
Number of subjects: 346
Study: 22858919

Group type: EXPERIMENTAL
Intervention: Paclitaxel (10, 50, 100, or 200 µM) dissolved in iopromide (contrast medium)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (iopromide without paclitaxel)
Number of subjects: 24
Study: 21207920

Group type: EXPERIMENTAL
Intervention: 7.5% calcium sodium phosphosilicate (NovaMin) dentifrice
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 0.4% stannous fluoride gel
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 5% potassium nitrate dentifrice
Number of subjects: 120
Study: 18494967

Group type: EXPERIMENTAL
Intervention: Ozone followed by P (8% carbamide peroxide solution)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ozone concurrently with P (8% carbamide peroxide solution)
Number of subjects: 60

Group type: COMPARATOR
Intervention: P alone (8% carbamide peroxide solution)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ozone followed by P/TM (50:50 blend)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ozone concurrently with P/TM (50:50 blend)
Number of subjects: 60

Group type: COMPARATOR
Intervention: P/TM (50:50 blend) alone
Number of subjects: 60
Study: 16435615

Group type: EXPERIMENTAL
Intervention: 7.5 mg of 0.75% ropivacaine + 25 microg of fentanyl
Number of subjects: 64

Group type: COMPARATOR
Intervention: 10 mg of 1% ropivacaine + 25 microg of fentanyl
Number of subjects: 64
Study: 14559423

Group type: EXPERIMENTAL
Intervention: New table for microscopes
Number of subjects: 10

Group type: COMPARATOR
Intervention: Old non-adjustable laboratory table
Number of subjects: 10
Study: 10099655

Group type: EXPERIMENTAL
Intervention: Adjuvant low-dose radiation therapy (LDRT) after chemotherapy with MOPP/ABVD
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Adjuvant low-dose radiation therapy (LDRT) after chemotherapy with ABVD
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Adjuvant low-dose radiation therapy (LDRT) after chemotherapy with MOPP/ABVD or ABVD
Number of subjects: 24
Study: 8735734

Group type: EXPERIMENTAL
Intervention: Surgical castration (total abdominal hysterectomy and bilateral salpingo‐oophorectomy)
Number of subjects: 27
Study: 2015545

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5FU) plus doxorubicin as adjuvant chemotherapy
Number of subjects: 125

Group type: COMPARATOR
Intervention: Observation (control group)
Number of subjects: 125
Study: 6779618

Group type: EXPERIMENTAL
Intervention: Nifedipine, 10 mg buccally
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31557380

Group type: EXPERIMENTAL
Intervention: Metformin (1,700 mg/day)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study: 29519921

Group type: EXPERIMENTAL
Intervention: 50 mg prednisone for 7 days
Number of subjects: 310

Group type: COMPARATOR
Intervention: Placebo for 7 days
Number of subjects: 310
Study: 26346638

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) 50 or 70 mg/day
Number of subjects: 773

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 773

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) 50 and 70 mg/day
Number of subjects: 773

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX)
Number of subjects: 773
Study: 24940656

Group type: EXPERIMENTAL
Intervention: Intensive ambulatory multidisciplinary rehabilitation
Number of subjects: 106

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 106
Study: 21176916

Group type: EXPERIMENTAL
Intervention: Helmet use (after legislation)
Number of subjects: 1684

Group type: COMPARATOR
Intervention: Helmet use (before legislation)
Number of subjects: 1684

Group type: EXPERIMENTAL
Intervention: Head injury
Number of subjects: 1684

Group type: EXPERIMENTAL
Intervention: Abdominal injury
Number of subjects: 1684
Study: 20816122

Group type: EXPERIMENTAL
Intervention: Amlodipine + Candesartan
Number of subjects: 2049

Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 2049
Study: 17627903

Group type: EXPERIMENTAL
Intervention: Intrastricture steroid injection (triamcinolone, 40 mg total dose)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 13
Study: 16210155

Group type: EXPERIMENTAL
Intervention: Peripheral foot blockade
Number of subjects: 51

Group type: COMPARATOR
Intervention: Popliteal sciatic nerve block
Number of subjects: 51
Study: 12389594

Group type: EXPERIMENTAL
Intervention: Transdermal estrogens (50 microg 17 beta‐Estradiol/24 hr)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Transdermal estrogens with progestagens (10 mg daily for last 2 weeks)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Transdermal estrogens
Number of subjects: 17
Study: 12394541

Group type: EXPERIMENTAL
Intervention: Group 1 (55% water content)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Group 2 (38% water content)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Group 3 (Dk value of 90)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Group 4 (Dk value of 52)
Number of subjects: 56
Study: 9649908

Group type: EXPERIMENTAL
Intervention: Percentage of type I muscle fibres and relative fibre area of type I
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Capillary density (number of capillaries/muscle fibre)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Diffusion distance (fibre area supplied by one capillary)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Activities of LPL and citrate synthase
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Activity of LPL
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Insulin/C-peptide ratio
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Muscle fibre distribution variables
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Insulin/C-peptide ratio (excluding muscle morphological variables)
Number of subjects: 24
Study: 8077174

Group type: EXPERIMENTAL
Intervention: Lithium treatment (sustained-release form, once a day at night, optimum dosage with plasma level of 0.5-0.79 mmol/L 12 hours after the nightly dose)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Lithium treatment (lower dosage after 1982)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Lithium treatment
Number of subjects: 103
Study: 2511685

Group type: EXPERIMENTAL
Intervention: Buccal NTG (1-3 mg t.i.d., five hourly with an eight-h washout period)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 830201

Group type: EXPERIMENTAL
Intervention: Real-time, two-dimensional echocardiography
Number of subjects: 105

Group type: COMPARATOR
Intervention: Biplane cineangiography
Number of subjects: 105
Study: 30640637

Group type: EXPERIMENTAL
Intervention: Mirroring group (parents watching VR tour through mirroring display)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (children watching VR tour via head mounted display)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Mirroring group
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study: 26783978

Group type: EXPERIMENTAL
Intervention: 0.2% hyaluronic acid (Visaid)
Number of subjects: 16

Group type: COMPARATOR
Intervention: 0.9% saline solution
Number of subjects: 16
Study: 25387438

Group type: EXPERIMENTAL
Intervention: Pocket-sized ultrasound
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no ultrasound)
Number of subjects: 40
Study: 23870440

Group type: EXPERIMENTAL
Intervention: Responsive Classroom (RC) training
Number of subjects: 239

Group type: COMPARATOR
Intervention: Control (business as usual)
Number of subjects: 239
Study: 21986218

Group type: EXPERIMENTAL
Intervention: DSJI (Disposable-Syringe Jet Injector)
Number of subjects: 60

Group type: COMPARATOR
Intervention: N-S (Needle-Syringe)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: DSJI
Number of subjects: 60

Group type: COMPARATOR
Intervention: N-S
Number of subjects: 60
Study: 17928803

Group type: EXPERIMENTAL
Intervention: 8% (w/w) solution of galactose (Gal)
Number of subjects: 9

Group type: COMPARATOR
Intervention: 8% solution of 50% galactose/50% glucose (Gluc/Gal)
Number of subjects: 9

Group type: COMPARATOR
Intervention: 8% solution of 80% glucose/20% fructose (Gluc/Fru)
Number of subjects: 9
Study: 17125431

Group type: EXPERIMENTAL
Intervention: B2000 needle-free device
Number of subjects: 27
Study: 15592281

Group type: EXPERIMENTAL
Intervention: CTG, fetal scalp blood sampling, and continuous fetal pulse oximetry (study group)
Number of subjects: 146

Group type: COMPARATOR
Intervention: CTG and fetal scalp blood sampling (control group)
Number of subjects: 146
Study: 11304505

Group type: EXPERIMENTAL
Intervention: Serum creatinine
Number of subjects: 2394

Group type: EXPERIMENTAL
Intervention: Serum uric acid
Number of subjects: 2394
Study: 9282547

Group type: EXPERIMENTAL
Intervention: Cervitec varnish
Number of subjects: 198

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 198
Study: 8512659

Group type: EXPERIMENTAL
Intervention: Ro 42-5892 (600 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 3805544

Group type: EXPERIMENTAL
Intervention: Histamine (0.1 mg per nostril)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Histamine (0.5 mg per nostril)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Histamine (5 mg per nostril)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Histamine (10 mg per nostril)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline (nebulized normal saline)
Number of subjects: 10
Study: 31053954

Group type: EXPERIMENTAL
Intervention: Tolvaptan (weight-adjusted doses, titrated to maintenance dose)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Tolvaptan
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 28964657

Group type: EXPERIMENTAL
Intervention: Virtual Reality Simulator
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Box Trainer
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control (No Training)
Number of subjects: 36
Study: 26168325

Group type: EXPERIMENTAL
Intervention: Affect Consciousness (AC)
Number of subjects: 63
Study: 24510471

Group type: EXPERIMENTAL
Intervention: Memantine 20 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 22840257

Group type: EXPERIMENTAL
Intervention: Nasal fluticasone furoate (FF)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 21261107

Group type: EXPERIMENTAL
Intervention: Perindopril (5 mg once daily, n = 20)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Rilmenidine (1 mg once daily, n = 18)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Telmisartan (40 mg once daily, n = 16)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo (n = 23)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Healthy subjects (n = 50)
Number of subjects: 54
Study: 17919555

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate nasal spray 110 microg QD for 2 weeks
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo nasal spray QD for 2 weeks
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate nasal spray
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo nasal spray
Number of subjects: 53
Study: 16246948

Group type: EXPERIMENTAL
Intervention: cilostazol 100 mg BID for 6 months
Number of subjects: 705

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 705

Group type: EXPERIMENTAL
Intervention: cilostazol
Number of subjects: 705
Study: 14605480

Group type: EXPERIMENTAL
Intervention: ARNICA D12
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 11243072

Group type: EXPERIMENTAL
Intervention: Purified Verocell Rabies Vaccine (PVRV)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Non-pregnant women (control group)
Number of subjects: 17
Study: 8888092

Group type: EXPERIMENTAL
Intervention: Aztreonam-clindamycin (A-C)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Gentamicin-clindamycin (G-C)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Infected patients
Number of subjects: 85

Group type: COMPARATOR
Intervention: Noninfected patients
Number of subjects: 85
Study: 1891675

Group type: EXPERIMENTAL
Intervention: Topical vitamin A acid at 0.025% for 6 months followed by 0.05%
Number of subjects: 0
Study: 6130243

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional treatment (UCT)
Number of subjects: 30
Study: 3720528

Group type: EXPERIMENTAL
Intervention: Diazepam (DZ) 80 mg every third day (3 subjects) or every sixth day (3 subjects) for a total of 3-6 dosing occasions
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Triazolam (TZ) 2.0 or 3.0 mg every second day (4 subjects) or every third day (2 subjects) for a total of 3-5 dosing occasions
Number of subjects: 11
Study: 30382270

Group type: EXPERIMENTAL
Intervention: Strawberry supplementation (50 g day-1 for 12 weeks)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo (50 g day-1, matched for calories and fiber)
Number of subjects: 17
Study: 28853317

Group type: EXPERIMENTAL
Intervention: 8 mm then 4 mm drop shoes (EXP)
Number of subjects: 30

Group type: COMPARATOR
Intervention: 12 mm drop shoes (CON)
Number of subjects: 30
Study: 25684620

Group type: EXPERIMENTAL
Intervention: 5 mL Evicel® (fibrin haemostatic sealant)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Untreated (control group)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cost of treatment with Evicel®
Number of subjects: 60
Study: 23391304

Group type: EXPERIMENTAL
Intervention: Mobile app (on mobile phone or iPad)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Computer
Number of subjects: 35
Study: 20578381

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (therapeutic principle of dredging meridians and collaterals, tonifying qi and eliminating blood stasis, supplementing liver and kidney, nourishing blood and tendon; points included Hegu (LI 4), Taichong (LR 3), Zusanli (ST 36), Qihai (CV 6), Quchi (LI 11))
Number of subjects: 64

Group type: COMPARATOR
Intervention: Cobamamide (intramuscular injection)
Number of subjects: 64
Study: 18227370

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 42418

Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 42418

Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 42418
Study: 17016485

Group type: EXPERIMENTAL
Intervention: Level-III dissection (group-A, n=258)
Number of subjects: 514

Group type: COMPARATOR
Intervention: Level-I dissection (group-B, n=256)
Number of subjects: 514

Group type: EXPERIMENTAL
Intervention: Level-III dissection (group-A)
Number of subjects: 514

Group type: COMPARATOR
Intervention: Level-I dissection (group-B)
Number of subjects: 514
Study: 11952999

Group type: EXPERIMENTAL
Intervention: UVA exposure
Number of subjects: 53

Group type: COMPARATOR
Intervention: No UVA exposure (Control)
Number of subjects: 53
Study: 9828757

Group type: EXPERIMENTAL
Intervention: Alpha-linolenic acid-rich diet (n=15)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Linoleic acid-rich diet (n=14)
Number of subjects: 29
Study: 7926539

Group type: EXPERIMENTAL
Intervention: One hypertonic phosphate enema 1 hour before fiberoptic flexible sigmoidoscopy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Two hypertonic phosphate enemas 1 hour before fiberoptic flexible sigmoidoscopy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: One enema 3 hours before and a second enema 1 hour before fiberoptic flexible sigmoidoscopy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not explicitly mentioned
Number of subjects: 0
Study: 2510510

Group type: EXPERIMENTAL
Intervention: OKT3 prophylaxis (14 days post-transplant)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Triple-drug immunosuppressant therapy (cyclosporine, azathioprine, prednisone)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: OKT3 prophylaxis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: OKT3 prophylaxis with 2 g intravenous methylprednisolone
Number of subjects: 0
Study: 776312

Group type: EXPERIMENTAL
Intervention: Phenothiazine withdrawal
Number of subjects: 31

Group type: COMPARATOR
Intervention: Active medication (control group)
Number of subjects: 31
Study: 30043569

Group type: EXPERIMENTAL
Intervention: Modified clinical nursing protocol
Number of subjects: 120

Group type: COMPARATOR
Intervention: Conventional epilepsy nursing protocol
Number of subjects: 120
Study: 27594602

Group type: EXPERIMENTAL
Intervention: Psychoanalytic Therapy (PT)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 200
Study: 24801367

Group type: EXPERIMENTAL
Intervention: Higher-protein, higher-haem iron diet (HPHI)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Lower-protein, lower-haem iron diet (LPLI)
Number of subjects: 76
Study: 22390832

Group type: EXPERIMENTAL
Intervention: One-hour in vivo exposure treatment
Number of subjects: 32

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 32
Study: 20535921

Group type: EXPERIMENTAL
Intervention: Tiantai No. 1 (TT1)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study: 18717242

Group type: EXPERIMENTAL
Intervention: Inhaled human insulin (Exubera)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Subcutaneous insulin
Number of subjects: 121
Study: 16448231

Group type: EXPERIMENTAL
Intervention: Intrusion with continuous force of 100 cN for eight weeks
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Extrusion with continuous force of 100 cN for eight weeks
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 9
Study: 14520165

Group type: EXPERIMENTAL
Intervention: Modafinil 400 mg once daily
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Modafinil 400 mg split dose
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Modafinil 200 mg once daily
Number of subjects: 32

Group type: COMPARATOR
Intervention: Modafinil (all doses)
Number of subjects: 32
Study: 10416152

Group type: EXPERIMENTAL
Intervention: Korean children with Class III malocclusions
Number of subjects: 141

Group type: COMPARATOR
Intervention: European-American children with Class III malocclusions
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Thin-plate spline analysis
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Partial warp (PW) 8
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Partial warp (PW) 9, PW4, PW5
Number of subjects: 141
Study: 7494611

Group type: EXPERIMENTAL
Intervention: Regenerated cellulose low‐flux membrane, followed by regenerated cellulose high‐flux membrane, and then polymethylmethacrylate (PMMA) high‐flux membrane
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Regenerated low‐flux cellulose membrane, followed by PMMA low‐flux membrane and PMMA high‐flux membrane
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Same membrane throughout the 6‐week study period
Number of subjects: 18
Study: 2098372

Group type: EXPERIMENTAL
Intervention: Defibrotide
Number of subjects: 40

Group type: COMPARATOR
Intervention: Low-dose subcutaneous heparin (LDSH)
Number of subjects: 40
Study: 552657

Group type: EXPERIMENTAL
Intervention: Fenoterol aerosol (400 micrograms)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Isoproterenol aerosol (200 micrograms)
Number of subjects: 59
Study: 30975019

Group type: EXPERIMENTAL
Intervention: Cream denture adhesive
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Powder denture adhesive
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control (saline solution)
Number of subjects: 200
Study: 30133938

Group type: EXPERIMENTAL
Intervention: Functional training (FT) programme for 10 weeks
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 38
Study: 27591988

Group type: EXPERIMENTAL
Intervention: Topical therapy
Number of subjects: 407

Group type: EXPERIMENTAL
Intervention: Combined topical and NB-UVB therapy
Number of subjects: 407

Group type: COMPARATOR
Intervention: NB-UVB therapy
Number of subjects: 407
Study: 25386609

Group type: EXPERIMENTAL
Intervention: Cynatine HNS (500 mg keratin plus vitamins and minerals)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 50
Study: 22788983

Group type: EXPERIMENTAL
Intervention: Life-review therapy with computer supplements (6 weeks)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 36